Sun Pharma Announces the Availability of ILUMYA (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis
Deepthi | Myequity news | Date : 23-10-2018 16:50:00 IST
Sun Pharmaceutical Industries Ltd., today announced that moderate-to-severe psoriasis treatment ILUMYA (tildrakizumab-asmn) 100 mg/mL is now available in the United States. ILUMYA is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
“The availability of ILUMYA is an important milestone for Sun Pharma as we expand our specialty medicine portfolio in the U.S. ILUMYA offers a new, safe and effective treatment option for people who are still struggling to manage their moderate-to-severe plaque psoriasis,” said Abhay Gandhi, Chief Executive Officer, Sun Pharma, North America. “We understand the importance of patient and physician choice, and are committed to making ILUMYA among the most cost-effective treatments on the market today.” About Sun Pharmaceutical Industries Ltd.:
“For nearly 20 years, my psoriasis has disrupted my life in many ways. I never imagined the impact of dealing with flaking and peeling skin,” said Mary Robinson, a tildrakizumab clinical trial participant. “After a couple doses of ILUMYA my skin started to improve, and I’m encouraged by the ongoing results that help me keep my psoriasis under control.”
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 42 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.